How, when, and why to use apolipoprotein B in clinical practice

American Journal of Cardiology

Volumn 90, Issue 8 SUPPL., 2002, Pages 48-54

  Sniderman, Allan D ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ACCURACY; CALCULATION; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CORONARY ARTERY DISEASE; DIAGNOSTIC VALUE; DRUG EFFICACY; DYSLIPIDEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; METHODOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; STANDARDIZATION;

EID: 0037126378     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)02633-4     Document Type: Article

References (32)

1. Adult Treatment Panel III . Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA. 285:2001;2486-2497.
2. Sniderman A.D., Scantlebury T., Cianflone K. Hypertriglyceridemic hyperapoB the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus . Ann Intern Med. 135:2001;447-459.
3. Lamarche B., Moorjani S., Lupien P.J., Cantin B., Bernard P.M., Dagenais G.R., Despres J.P. Apoprotein A-1 and B levels and the risk of ischemic heart disease during a 5-year follow-up of men in the Québec Cardiovascular Study. Circulation. 94:1996;273-278.
4. Sharrett A.R., Ballantyne C.M., Coady S.A., Heiss G., Sorlie P.D., Catellier D., Patsch W. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions the Atherosclerosis Risk in Communities (ARIC) Study . Circulation. 104:2001;1108-1113.
5. Walldius G., Jungner I., Holme I., Aastveit A.H., Kolar W., Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study) a prospective study . Lancet. 358:2001;2026-2033.
6. Marcovina S.M., Albers J.J., Kennedy H., Mei J.V., Henderson L.O., Hannon W.H. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of international reference material. Clin Chem. 40:1994;586-592.
7. Contois J.H., McNamara J.R., Lammi-Keefe C.J., Wilson P.W., Massov T., Schaefer E.J. Reference intervals for plasma apolipoprotein B determined with a standardized commercial immunoturbidimetric assay results from the Framingham Offspring Study . Clin Chem. 42:1996;515-523.
8. Connelly P.W., Poapst M., Davignon J., Lussier-Cacan S., Reeder B., Lessard R. Reference values of plasma apolipoproteins A-I and B, and association with nonlipid risk factors in the populations of two Canadian provinces Quebec and Saskatchewan. Canadian Heart Health Surveys Research Group . Can J Cardiol. 15:1999;409-418.
9. Rubies-Prat J., Reverter J.C., Senti M., Pedro-Botet J., Salinas I., Lucas A., Nogues X., Samarti A. Calculated low-density lipoprotein cholesterol should not be used for management of lipoprotein abnormalities in patients with diabetes mellitus. Diabetes Care. 16:1993;1081-1086.
10. McNamara J.R., Cohn J.S., Wilson P.W., Schaefer E.J. Calculated values for low-density lipoprotein cholesterol in the assessment of lipid abnormalities and coronary disease risk. Clin Chem. 36:1990;36-42.
11. Rifai N., Warnick G.R., McNamara J.R., Belcher J.D., Grinstead G.F., Frantz I.D.J. Measurement of low-density-lipoprotein cholesterol in serum a status report . Clin Chem. 38:1992;150-160.
12. Joven J., Villabona C., Vilella E., Masana L., Alberti R., Valles M. Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. N Engl J Med. 323:1990;579-584.
13. Matas C., Cabre M., La Ville E., Prats E., Joven J., Turner P.R., Masana L., Camps J. Limitations of the Friedewald formula for estimating low-density lipoprotein cholesterol in alcoholics with liver disease. Clin Chem. 40:1994;404-406.
14. Scharnagl H., Nauck M., Wieland H., März W. The Friedewald formula underestimates LDL cholesterol at low concentrations. Clin Chem Lab Med. 39:2001;426-431.
15. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 18:1972;499-502.
16. Bachorik P.S., Ross J.W. National Cholesterol Education Program recommendations for measurement of low-density lipoprotein cholesterol executive summary. The National Cholesterol Education Program Working Group on Lipoprotein Measurement . Clin Chem. 41:1995;1420-1441.
17. Durrington P.N. Can measurement of apolipoprotein B replace the lipid profile in the follow-up of patients with lipoprotein disorders? Clin Chem. 48:2002;401-402.
18. Gotto A.M. Jr, Whitney E., Stein E.A., Shapiro D.R., Clearfield M., Weis S., Jou J.Y., Langendorfer A., Beere P.A., Watson D.J., Downs J.R., de Cani J.S. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation. 101:2000;477-484.
19. Pedersen T.R., Olsson A.G., Faergeman O., Kjekshus J., Wedel H., Berg K. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation. 97:1998;1453-1460.
20. Moss A.J., Goldstein R.E., Marder V.J., Sparks C.E., Oakes D., Greenberg H., Weiss H.J., Zareba W, Brown M.W., Liang C.S., Lichstein E., Little W.C., Gillespie J.A., Van Voorhees L., Krone R.J., Bodenheimer M.M., Hochman J., Dwyer E.M. Jr, Arora R., Marcus F.I., Watelet L.F., Case R.B. Thrombogenic factors and recurrent coronary events. Circulation. 99:1999;2517-2522.
21. Roeters van Lennep J.E., Westerveld T., Roeters van Lennep W.O., Zwinderman A.H., Erkelens D.W., van der Wall E.E. Apolipoprotein concentrations during treatment and recurrent coronary artery disease events. Arterioscler Thromb Vasc Biol Dis. 20:2000;2408-2413.
22. Simes R.J., Marschner I.C., Hunt D., Colquhoun D., Sullivan D., Stewart R.A., Hague W., Keech A., Thompson P., White H., Shaw J., Tonkin A., The LIPID Study Investigators . Relationship between lipid levels and clinical outcomes in Long-term Intervention with Pravastatin in Ischemic Disease (LIPID). To what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation. 105:2002;1162-1169.
23. Collins-Nakai R.L.C., Dagenais G.R. The role of the cardiovascular specialist in the prevention of cardiovascular diseases - executive summary. Can J Cardiol. 15:1999;7G-10G.
24. Elovson J., Chatterton J.E., Bell G.T., Schumaker V.N., Reuben M.A., Puppione D.L., Reeve J.R. Jr, Young N.L. Plasma very low density lipoproteins contain a single molecule of apolipoprotein B. J Lipid Res. 29:1988;1461-1473.
25. Krauss R.M., Burke D.J. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res. 23:1982;97-104.
26. Teng B., Thompson G.R., Sniderman A.D., Forte T.M., Krauss R.M., Kwiterovich P.O. Composition and distribution of low density lipoprotein fractions in hyperapobetalipoproteinaemia, normolipidaemia and familial hypercholesterolaemia. Proc Natl Acad Sci U S A. 80:1983;6662-6666.
27. Lamarche B., Tchernof A., Moorjani S., Cantin B., Dagnais G.R., Lupien P.J., Despres J.P. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation. 95:1997;69-75.
28. Sniderman A.D., Wolfson C., Teng B., Franklin F.A., Bachorik P.S., Kwiterovich P.O. Jr. Association of hyperapobetalipoproteinemia with endogenous hypertriglyceridemia and atherosclerosis. Ann Intern Med. 97:1982;833-839.
29. Veniant M.M., Withycombe S., Young S.G. Lipoprotein size and atherosclerosis susceptibility in Apoe-/- and Ldlr-/- mice. Arterioscler Thromb Vasc Biol. 21:2001;1567-1570.
30. Griffin B.A., Freeman D.J., Tait G.W., Thomson J., Caslake M.J., Packard C.J., Shepherd J. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions relative contribution of small, dense LDL to coronary heart disease risk . Atherosclerosis. 106:1994;241-253.
31. Demacker P.N., Veerkamp M.J., Bredie S.J., Marcovina S., de Graaf J., Stalenhoef A.F. Comparison of the measurement of lipids and lipoproteins versus assay for apoliprotein B for estimation of coronary heart disease risk a study in familial combined hyperlipidemia . Atherosclerosis. 153:2000;483-490.
32. Genest J. Jr, Bard J.M., Fruchart J.C., Ordovas J.M., Schaefer E.J. Familial hypoalphalipoproteinemia in premature coronary artery disease. Arterioscler Thromb Vasc Biol. 13:1993;1728-1737.